Lotus Pharmaceuticals, Inc.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. carries a market capitalization of 10.56M, placing it among publicly traded companies globally. Its enterprise value stands at 15.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. has 27.80M shares outstanding.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 5.98. The price-to-sales ratio is 0.15, and the price-to-book ratio stands at 0.11.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 5.37 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.63 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.82M versus a market cap of 10.56M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.44, indicating elevated leverage, while an interest coverage ratio of 11.87 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2011, Lotus Pharmaceuticals, Inc. posted a return on equity (ROE) of 1.82, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.55, measuring how efficiently the asset base is converted into earnings. The company generates approximately 132,821.74 in revenue per employee across its workforce of 533.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 37.27 indicates how many times Lotus Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2011, Lotus Pharmaceuticals, Inc. recorded an income tax benefit of -250,073.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.49M, leaving 1.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 20, 2026, Lotus Pharmaceuticals, Inc.'s stock has gained approximately 22.50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended September 30, 2011, Lotus Pharmaceuticals, Inc. generated 70.79M in revenue and converted that into 1.74M in net income, yielding earnings per share of 0.06. EBITDA reached 2.95M, while operating income came in at 7.57M.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. holds 158,908.00 in cash and equivalents against 5.41M in total debt, resulting in a net debt position of 5.25M. Total book value stands at 99.45M, with working capital of -6.64M providing operational flexibility.

Lotus Pharmaceuticals, Inc. produced 18.37M in operating cash flow over the twelve months ended September 30, 2011. After subtracting -19.17M in capital expenditures, free cash flow totaled -802,955.00 - equivalent to -0.03 per share.

Over the twelve months ended September 30, 2011, Lotus Pharmaceuticals, Inc. posted a gross margin of 35.10, reflecting its pricing power and cost economics. The operating margin of 10.69 and net profit margin of 2.45 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2011. Free cash flow yield is negative at -7.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Lotus Pharmaceuticals, Inc.'s most recent stock split took place on December 31, 2010 with a 2:1 split ratio.

As of September 30, 2011, Lotus Pharmaceuticals, Inc. has an Altman Z-Score of 1.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.